Abstract: Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkB?, PSI, a nucleotide sequence encoding IkB? anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.

Abstract: Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkB?, PSI, a nucleotide sequence encoding IkB? anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.

Abstract: A method for providing information for deciding on a therapeutic strategy for a patient, comprising the step of assessing the activity of a transcription factor in a cell or cells from the patient, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a promoter under the control of the transcription factor (transcription factor-dependent promoter); and (2) assessing the expression of the reporter gene in the said cell or cells. A method for characterising the hormone dependency of a primary cancer cell or cells, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a hormone-dependent promoter; and (2) assessing the expression of the reporter gene in the said cell or cells.

Abstract: Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inbitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkB&agr;, PSI, a nucleotide sequence encoding IkB&agr; anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.